Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

167 Views

241. PK/PD Studies: Saturday, 12:15 - 1:30 p.m.

Poster Session: PK/PD Studies

(2532) Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia

Saturday, October 14, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Sujata M. Bhavnani, PharmD; MS; FIDSA

Executive Vice President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States

JH

Jeffrey P. Hammel, MS

Director
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
KL

Kathryn Liolios, MA

Statistician
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
AC

Anthony P. Cammarata, M.S.

Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
MS

Mikael Saulay, MSc

Basilea Pharmaceutica International Ltd
Allschwil, Basel-Landschaft, Switzerland
CR

Christopher M. Rubino, PharmD

Executive Vice President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
Marc Engelhardt, MD (he/him/his)

Dr.
Basilea Pharmaceutica International Ltd., Allschwil, Switzerland
Allschwil, Basel-Landschaft, Switzerland
JS

Jennifer Smart, PhD

Sr. Microbiologist, Development
Basilea Pharmaceutica International Ltd
Allschwil, Basel-Landschaft, Switzerland
MJ

Mark E. Jones, PhD

Basilea Pharmaceutica International Ltd., Allschwil, Switzerland
Allschwil,, Basel-Landschaft, Switzerland
PA

Paul G. Ambrose, PharmD; MS; FIDSA

President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
KL

Karine Litherland, Ph.D.

Basilea Pharmaceutica International Ltd
Allschwil,, Basel-Landschaft, Switzerland